Omeprazole: uses, product-specific instructions and important interactions

What is omeprazole used for?

Omeprazole, including products sold under the name Losec, is a proton-pump inhibitor (PPI): a medicine that reduces stomach acid. Depending on the product and indication, it is used for reflux, heartburn, stomach or duodenal ulcers, and with antibiotics for Helicobacter pylori infection.

Authorisation and prescription status depend on the country and actual presentation, not simply on whether the dose is “low”. This guide uses the Spanish Omeprazol Cinfamed 20 mg and Omeprotect 20 mg product information as specific examples. It does not establish current stock or suitability. See the omeprazole information page for related information.

How it works

Stomach cells produce acid using the H+/K+ ATPase, known as the proton pump. Omeprazole inhibits this pump. Relief can build over several days; it is not an instant-relief antacid. Do not increase your dose because symptoms have not improved immediately.

PPIs, H2 blockers such as famotidine, and antacids work differently. Choosing between them depends on the diagnosis and your other medicines, not a general ranking of which is best for everyone.

Uses and product-specific instructions

The Cinfamed prescription information includes gastro-oesophageal reflux disease and oesophagitis, stomach and duodenal ulcers, H. pylori eradication with antibiotics, and treatment or prevention of NSAID-associated ulcers in appropriate patients. These are not all indications for every non-prescription presentation.

The table describes product information, not a self-treatment or antibiotic-eradication protocol. Do not transfer one product's course to another indication. See Cinfamed sections 4.1–4.2 and Omeprotect sections 4.1–4.2.

Common side effects

The product information lists headache, abdominal pain, nausea or vomiting, diarrhoea, constipation and wind among common effects. If symptoms are persistent or troublesome, ask a healthcare professional. Do not assume every new symptom is an expected minor side effect.

Reviewing longer-term use

Continuing treatment should be reviewed with a clinician. The product information describes these precautions:

• Magnesium: severe low magnesium has been reported after at least three months, most often after a year. Monitoring may be appropriate, particularly with interacting medicines.
• Fractures: observational evidence associates PPIs with a modest increase in certain fractures, especially at high doses and beyond one year. This does not prove causation or establish a safe several-year threshold.
• Vitamin B12: reduced absorption matters particularly when stores are low or other risk factors exist during long-term treatment; it is not confined to an established number of years.
• Intestinal infections: reduced acidity may increase susceptibility to certain infections.

These cautions do not mean you should stop a needed PPI. Review the lowest effective dose and necessary duration with the prescriber. Discuss how to stop or reduce long-term treatment safely with them. See Cinfamed section 4.4.

Omeprazole and clopidogrel

Omeprazole can reduce exposure to clopidogrel's active metabolite and its antiplatelet activity. The clinical importance for cardiovascular outcomes remains uncertain. As a precaution, the product information discourages concomitant omeprazole and clopidogrel.

If you take clopidogrel, ask the prescriber or pharmacist to review acid-suppression treatment. Do not stop clopidogrel, switch to pantoprazole yourself, or assume separating doses solves the interaction. This article does not establish a universally preferred replacement PPI. See Cinfamed sections 4.4–4.5.

Contraindications, interactions and alarm symptoms

Omeprotect contraindicates hypersensitivity to omeprazole, substituted benzimidazoles or its excipients, and concomitant nelfinavir. Concomitant atazanavir is not recommended. These are distinct from interactions managed by monitoring. Do not stop an antiretroviral yourself; contact your treating clinician about the combination. See Omeprotect sections 4.3–4.5.

Give the clinician a complete medicine list, including clopidogrel and antifungals such as ketoconazole or itraconazole, whose absorption may be affected. Liver disease can affect dosing. If an endoscopy or other investigation is planned, discuss PPI use and timing because treatment may mask symptoms or affect assessment.

Difficulty swallowing, unexplained weight loss, vomiting blood or black stools need urgent medical assessment. Persistent or worsening reflux also needs review. Do not treat these signs only with a PPI or wait for an online assessment. Call 112 for an emergency.

Prescrivia and access

Prescrivia provides technology to connect patients with independent EU-registered doctors and licensed pharmacies. It does not provide medical care or prescribe medicines. A doctor decides whether a PPI, tests or an in-person referral is appropriate; no prescription or outcome is guaranteed. The pharmacy is responsible for dispensing.

Spain prohibits distance sale of prescription medicines. Online sale of a non-prescription presentation has separate pharmacy requirements; neither status nor a lawful supply route can be inferred just from “omeprazole 20 mg”. See AEMPS's websites and apps notice. Country-specific arrangements need verification before any access claim.

Sources and review limits

The linked Cinfamed and Omeprotect product information supports the named examples and warnings, not every presentation, an individual treatment plan or current availability. See the current clinical, legal and language review statuses for this edition. This article is general information, not medical advice.

Related reading

• Online Medicine Safety: How to Check a Pharmacy
• How Online Doctor Consultations Work